Urinary metabolomic profile and gastric cancer

Mar 08, 2011

A research team from China investigated urinary metabolites expression changes among three mice groups using gas chromatography/mass spectrometry. Ten metabolites have differences between the normal group and the cancer group (non-metastasis group and metastasis group). Furthermore, seven metabolites with characteristic expression levels were identified between non-metastasis group and metastasis group.

Metabolomics is a post-genomic research field for analysis of low molecular weight compounds in biological systems, and its approaches offer an analysis of metabolite level changes in biological samples. Recently, metabolomic method has shown great potentials in identifying the new diagnostic markers and therapeutic targets for cancers. However, metabolomic studies on cancer metastasis remain scarce.

A research article to be published on February 14, 2011 in the addresses this question. The authors used metabolomics, which is based on gas chromatography/mass spectrometry (GC/MS) technology, to study the urinary expression changes among three mice groups.

This is the first report on urinary metabolomic investigation in using GC/MS. Biomarkers discovered in this study are mainly low molecular weight metabolites, which are difficult to detect by traditional methods. On the basis of this research, the authors believe that urinary metabolomic information investigated by GC/MS might play a significant role in early diagnosis and screening metastasis or recurrence of gastric cancer.

Explore further: Immune checkpoint inhibitors may work in brain cancers

More information: Hu JD, Tang HQ, Zhang Q, Fan J, Hong J, Gu JZ, Chen JL. Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. World J Gastroenterol 2011; 17(6): 727-734 www.wjgnet.com/1007-9327/full/v17/i6/727.htm

add to favorites email to friend print save as pdf

Related Stories

Food quality improved with software

Oct 28, 2010

Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for the analysis software TagFinder to Metabolomic Discoveries GmbH, a service provider in biochemical ...

A new molecular marker of gastric cancer

Mar 30, 2009

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate. TNM staging system is used worldwide to predict prognosis and direct therapeutic decisions of patients with GC. ...

Leukemia-related protein 16 and colorectal carcinoma

Apr 09, 2010

A research team from China investigated the expression of leukemia-related protein 16 (LRP16) in colorectal cancer and normal mucosas and possible relationship between LRP16 expression and clinicopathological variables. Their ...

Computer predicts anti-cancer molecules

Jun 17, 2008

A new computer-based method of analyzing cellular activity has correctly predicted the anti-tumour activity of several molecules. Research published today in BioMed Central's open access journal Molecular Cancer describes 'CoMet ...

MicroRNA-mediated metastasis suppression

Oct 28, 2009

Metastases are responsible for over 90% of cancer deaths. In the upcoming issue of G&D, Dr. Robert Weinberg (MIT) and colleagues lend molecular insight into how microRNAs suppress tumor metastasis.

Recommended for you

Immune checkpoint inhibitors may work in brain cancers

2 hours ago

New evidence that immune checkpoint inhibitors may work in glioblastoma and brain metastases was presented today by Dr Anna Sophie Berghoff at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.

New model of follow up for breast cancer patients

6 hours ago

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health ...

Immunotherapy set to revolutionise cancer treatment

7 hours ago

Immunotherapy is set to revolutionise the treatment of cancer, according to ESMO President Professor Rolf A. Stahel. His comments come as the ESMO Symposium on Immuno-Oncology 2014 is about to open in Geneva, Switzerland ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.